[Ustekinumab in a patient with Crohn's disease and anti-TNF-α-induced psoriasis]
| Autor: | Andrés, Sansó Sureda, Vicenç, Rocamora Durán, Amparo, Sapiña Camaró, Vanesa, Royo Escosa, María José, Bosque López |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Adult
Interleukin-12 Subunit p40 Tumor Necrosis Factor-alpha Adalimumab Antibodies Monoclonal Phototherapy Antibodies Monoclonal Humanized Combined Modality Therapy Infliximab Crohn Disease Adrenal Cortex Hormones Azathioprine Humans Psoriasis Drug Therapy Combination Female Ustekinumab Drug Eruptions Mesalamine Immunosuppressive Agents |
| Zdroj: | Gastroenterologia y hepatologia. 34(8) |
| ISSN: | 0210-5705 |
| Popis: | Treatment with anti-tumor necrosis factor (TNF)-α for Crohn's disease is relatively safe, although various cutaneous adverse effects have been reported such as the development or exacerbation of anti-TNF- α-induced psoriasis, which can sometimes lead to treatment withdrawal. Therefore, new alternative treatments with new mechanisms of action are required. Ustekinumab, a monoclonal antibody against the p40 subunit of interleukin 12/23, could induce response in patients with Crohn's disease and has demonstrated efficacy in patients with psoriasis. We present the case of a woman with Crohn's disease who developed psoriasis after treatment with two anti-TNF- α drugs (infliximab and adalimumab). The patient was subsequently treated with ustekinumab with resolution or psoriasis lesions and maintenance of remission of Crohn's disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|